NCT06997588: EPIK-P4: A Phase II Single-arm Study to Assess the Efficacy, Safety and Pharmacokinetics of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum (PROS)

Sponsor: Novartis Pharmaceuticals. Phase: PHASE2. Conditions: PIK3CA-related Overgrowth Spectrum (PROS)